Otsuka Corporation (TYO:4768)
Japan · Delayed Price · Currency is JPY 3,158.00
-22.00 (-0.69%)
At close: Dec 5, 2025
Otsuka Employees
Otsuka had 9,680 employees as of December 31, 2024. The number of employees increased by 472 or 5.13% compared to the previous year.
Employees
9,680
Change
472
Growth
5.13%
Revenue / Employee
133.38M JPY
Profits / Employee
6.55M JPY
Market Cap
1.20T
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 9,680 | 472 | 5.13% |
| Dec 31, 2022 | 9,208 | 37 | 0.40% |
| Dec 31, 2021 | 9,171 | 52 | 0.57% |
| Dec 31, 2020 | 9,119 | 387 | 4.43% |
| Dec 31, 2018 | 8,732 | 74 | 0.85% |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Fujitsu | 112,743 |
| Sony Group | 112,300 |
| TDK Corporation | 105,067 |
| NEC Corporation | 104,194 |
| Murata Manufacturing | 72,572 |
| Tokyo Electron | 19,573 |
| Kioxia Holdings | 15,042 |
| Keyence | 12,261 |
Otsuka News
- 11 days ago - FDA Approves Otsuka's (OTSKF) Voyxact for IgAN Treatment - GuruFocus
- 11 days ago - Otsuka gains FDA approval for sibeprenlimab for proteinuria reduction - Seeking Alpha
- 11 days ago - FDA Grants Accelerated Approval For Otsuka's VOYXACT In IgAN - Nasdaq
- 5 weeks ago - Otsuka 9-month Profit Rises; Revenue Up 5.1% - Nasdaq
- 5 months ago - Otsuka’s PTSD therapy draws efficacy concerns at FDA ahead of AdCom meeting - Seeking Alpha
- 5 months ago - SeaStar Medical's QUELIMMUNE Wins Prestigious Award From The National Kidney Foundation, Former Winners Include Names Like Janssen, Merck and Otsuka - Benzinga
- 6 months ago - Vera plunges as Otsuka outperforms with IgA nephropathy therapy - Seeking Alpha
- 6 months ago - Otsuka Announces FDA Acceptance and Priority Review of Biologics License Application (BLA) for Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN) - Benzinga